Navigation Links
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
Date:9/19/2013

afety and dosing profile over current therapies
  • Studies by the National Cancer Institute and DelMar have shown VAL-083 to have activity against a range of cancers, including glioblastoma
  • DelMar is conducting a Phase I/II clinical trial for VAL-083 at UC San Francisco and the Sarah Cannon Research Institute in Nashville, Tennessee and Sarasota, Florida
  • VAL-083 has received orphan drug designation in Europe and the U.S.
  • Additional Information:

    About DelMar Pharmaceuticals

    Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

    For more information, please visit www.delmarpharma.com or follow us on Twitter

    SOURCE DelMar Pharmaceuticals
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
    (Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. ... be presenting at the Rodman & Renshaw 17th Annual Global ... Held at the St. Regis Hotel, ORYZON will be represented ... Dr. Buesa will present ... EDT, at the Fontainebleau Room (2nd Floor).  The company is ...
    (Date:8/27/2015)... 2015 The global compression ... 3.96 billion by 2022, according to a new report ... venous disorders such as deep vein thrombosis, leg ulcers, ... the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) , ... also expected to boost market growth over the forecast ...
    Breaking Medicine Technology:DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
    ... Mass., Jan. 23, 2012  Boston Scientific Corporation (NYSE: ... District of New Jersey has found all the asserted patents ... invalid and entered judgment in favor of Boston Scientific. ... Johnson alleged that Boston Scientific,s PROMUS® Everolimus-Eluting Coronary Stent System ...
    ... Premier Research Group announces the appointment of Etienne Drouet ... this position, Mr. Drouet will play a leading role ... Premier Research,s growing portfolio of oncology business. ... oncology acumen serving the needs of our customers," said ...
    Cached Medicine Technology:Boston Scientific Announces Favorable Ruling in Patent Infringement Case 2Boston Scientific Announces Favorable Ruling in Patent Infringement Case 3Premier Research Names Etienne Drouet Executive Director, Oncology Europe 2
    (Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
    (Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
    (Date:8/27/2015)... ... August 27, 2015 , ... For the first ... machine with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact ... that takes drink customization to a whole new level. This line of Nutri ...
    (Date:8/27/2015)... ... ... Susan Harris and the team at LifeStream Health Centre & ... post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is a unique ... tissue, revitalizing cells so they make more collagen, an essential component in vaginal cell ...
    (Date:8/27/2015)... ... 27, 2015 , ... Since its launch on August 16, ... offices in three counties, LA, Orange and San Bernardino. Their twenty physicians ... by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation is dedicated ...
    Breaking Medicine News(10 mins):Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
    ... of a naturally occurring fat molecule have the potential ... or damage, researchers report. , Through both the ... smooth, young skin inevitably becomes coarse and wrinkled. The ... both lower the production of new collagen while increasing ...
    ... percent of patients who recently underwent liver transplantation ... factors included having had biliary-enteric anastomosis (choledocho-jejunal or ... more than four red blood cell units transfused. ... of Liver Transplantation, a journal by John Wiley ...
    ... internet pharmacies and life-saving medicines, purchased online was ... Global Forum ... June 5 The European Alliance for Access ... research report,-- The Counterfeiting Superhighway. The report revealed ...
    ... Reps. Pomeroy, Capito, Berkley Leading,Respective Chambers, Letter Effort ... to Seniors, Medicare-Financed Nursing Home Care, WASHINGTON, ... and Alliance for Quality Nursing Home Care today ... and Reps. Earl,Pomeroy (D-ND), Shelley Moore Capito (R-WV) ...
    ... June 5 Fort Dodge Animal Health, a,division of ... of,ProHeart(R) 6, a unique heartworm preventative, to the U.S. ... Food and Drug,Administration,s Center for Veterinary Medicine (CVM) of ... support the decision,to return this life-saving product to the ...
    ... to restore function to a paralyzed limb? Or to ... are two of the several topics that will be ... by Case Western Reserve University. The conference will be ... Conference Center in Cleveland. , "Neural interfaces have already ...
    Cached Medicine News:Health News:Researchers determine risk factors for infection after liver transplantation 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 3Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 2Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 2Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 4Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 5Health News:Premier conference on neurotechnology and deep brain stimulation to be held in Cleveland June 16-18 2
    ...
    Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
    ... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
    Profix total knee system is intended for cemented use only....
    Medicine Products: